TIGIT+/CD4+ T cells are enriched in high-risk CLL patients, as identified by advanced disease stage, unmutated IGHV genes or unfavorable cytogenetics. This evidence concerns the gene TIGIT and B-cell chronic lymphocytic leukemia.